While serious psychiatric side effects such as anxiety, depression, and suicide ideation have prevented rimonabant from passing clinical trials (Manzanares et al., 2018), it supports the notion that CB1R antagonism may allow for the attenuation of substance use disorders. Here, CNR1 is linked to Anxiety.